Our Pricing

Oral GLP-1 for Weight Loss

Searching for oral GLP-1 weight loss UK options? At Cured Pharmacy, we offer Wegovy® Oral Tablets (semaglutide pill) from £135.00 providing a needle-free alternative to injectable GLP-1 treatments. Our UK-registered clinical team provides free online consultations, with transparent pricing shown before you start your assessment.

What Are Oral GLP-1 Medications for Weight Loss?

Oral GLP-1 medications are tablet formulations of glucagon-like peptide-1 receptor agonists, originally available only as injections. These treatments mimic natural hormones that regulate appetite, slow gastric emptying, and enhance feelings of fullness after meals [1]. The active ingredient, typically semaglutide, works by binding to GLP-1 receptors in the brain and digestive system to reduce hunger signals and calorie intake.

Until recently, GLP-1 medications required subcutaneous injection because the peptide structure breaks down rapidly in the digestive system. Pharmaceutical advances using absorption enhancers now allow oral delivery, making these treatments accessible to patients who prefer not to inject [2]. The MHRA has licensed Wegovy® Oral Tablets as the first oral semaglutide formulation specifically indicated for weight management in the UK.

Clinical trials demonstrate that oral semaglutide produces significant weight reduction when combined with reduced-calorie diet and increased physical activity. In the OASIS 1 trial, participants taking oral semaglutide 50mg achieved an average 15.1% body weight reduction over 68 weeks compared to 2.4% with placebo [1]. Results vary based on individual response, adherence to lifestyle modifications, and prescribed dosage.

Oral GLP-1 vs Injectable GLP-1: Key Differences

Both oral and injectable GLP-1 medications contain the same active ingredient—semaglutide—but differ in formulation, dosing schedule, and absorption characteristics. Injectable formulations like Wegovy deliver semaglutide directly into subcutaneous tissue once weekly, bypassing the digestive system entirely. Oral tablets require daily administration on an empty stomach with specific timing requirements to optimise absorption [2].

Injectable GLP-1 treatments typically produce slightly higher average weight loss in head-to-head comparisons. The STEP 1 trial showed 14.9% average weight reduction with weekly injectable semaglutide 2.4mg over 68 weeks [3], whilst oral formulations achieved 15.1% reduction at the 50mg daily dose in OASIS 1 [1]. However, individual responses vary considerably, and some patients achieve excellent results with oral therapy whilst preferring the convenience of tablet administration.

Tolerability profiles differ slightly between formulations. Gastrointestinal side effects—nausea, diarrhoea, constipation—occur with both routes but may present differently in timing and severity. Oral semaglutide requires strict dosing instructions: take on an empty stomach with no more than 120ml water, then wait 30 minutes before eating, drinking, or taking other medications. Injectable formulations offer more flexibility in timing and don't require fasting windows.

Choosing Between Oral and Injectable Formulations

Your UK prescriber will consider several factors when recommending oral versus injectable GLP-1 therapy. Patients with needle phobia, those who travel frequently, or individuals preferring daily routine over weekly injections may find oral tablets more suitable. Conversely, patients who struggle with strict morning medication schedules or have conditions affecting gastrointestinal absorption may achieve better results with injectable formulations. Both options require prescription and clinical assessment at Cured Pharmacy, where our team evaluates your medical history, weight management goals, and lifestyle factors to determine the most appropriate treatment.

How Oral Semaglutide Works for Weight Loss

Oral semaglutide activates GLP-1 receptors throughout the body, particularly in the hypothalamus region of the brain that regulates appetite and satiety. When you take the tablet, absorption enhancers help the peptide cross the stomach lining into the bloodstream, where it mimics the action of naturally occurring GLP-1 hormone [2]. This activation triggers multiple metabolic effects that support weight reduction.

The primary mechanism involves appetite suppression. Semaglutide slows gastric emptying, meaning food remains in your stomach longer, prolonging feelings of fullness after meals. Simultaneously, it acts on brain receptors to reduce hunger signals and food cravings, making it easier to adhere to reduced-calorie eating patterns [1]. Patients commonly report feeling satisfied with smaller portions and experiencing fewer intrusive thoughts about food between meals.

Secondary metabolic effects include improved insulin sensitivity and modest increases in energy expenditure. Whilst these effects contribute to overall weight management, the dominant mechanism remains reduced calorie intake through appetite regulation. Clinical trials show that weight loss occurs gradually over months, with most participants reaching maximum effect between 60-68 weeks of continuous therapy [1][3]. Treatment works best when combined with structured dietary changes and regular physical activity, as recommended by NICE guidelines for obesity management.

Expected Timeline and Results

Most patients begin noticing appetite changes within the first 2-4 weeks of starting oral semaglutide, though measurable weight loss typically becomes apparent after 8-12 weeks. Dosing follows a gradual escalation schedule, starting at lower doses to minimise gastrointestinal side effects, then increasing every 4 weeks until reaching the maintenance dose. Average weight loss in clinical trials reached 10% of baseline body weight by approximately 40 weeks, with continued gradual reduction through 68 weeks [1]. Individual results vary significantly based on adherence to medication schedule, dietary modifications, activity levels, and metabolic factors. Your prescriber will monitor progress through regular follow-up assessments.

Wegovy Oral Tablets: The UK's Licensed Oral GLP-1 Option

Wegovy® Oral Tablets represent the first MHRA-licensed oral semaglutide formulation specifically indicated for chronic weight management in the UK. Available at Cured Pharmacy from £135.00 this prescription medication offers a needle-free alternative for eligible patients with a body mass index of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea.

The oral formulation uses SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) as an absorption enhancer, protecting semaglutide from enzymatic degradation in the stomach and facilitating transport across the gastric epithelium [2]. Each tablet must be taken in the morning on an empty stomach with up to 120ml of water only, followed by a 30-minute fasting period before consuming food, beverages, or other oral medications. This strict administration schedule optimises bioavailability and therapeutic effect.

Wegovy Oral follows a dose escalation protocol starting at 3mg daily, increasing every 4 weeks through 7mg, 14mg, and eventually reaching the maintenance dose. Your UK prescriber determines the appropriate target dose based on your response, tolerability, and weight management goals. All Wegovy Oral prescriptions at Cured Pharmacy require completion of a clinical assessment by our registered prescribers, who evaluate your medical history, current medications, and suitability for GLP-1 therapy.

Who Can Take Oral GLP-1 Weight Loss Medication?

Oral GLP-1 medications are licensed for adults aged 18 and over with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related health condition. NICE guidance recommends GLP-1 receptor agonists as part of a comprehensive weight management programme that includes dietary modification, increased physical activity, and behavioural support [4]. Your prescriber assesses eligibility based on these criteria during your online consultation at Cured Pharmacy.

Certain medical conditions preclude oral GLP-1 use. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease including gastroparesis, and pregnancy or breastfeeding. Patients with a history of pancreatitis require careful evaluation, as GLP-1 medications have been associated with acute pancreatitis in rare cases [2]. Renal impairment doesn't require dose adjustment, but severe hepatic impairment warrants caution.

Drug interactions require consideration when prescribing oral semaglutide. Because it slows gastric emptying, oral GLP-1 can affect absorption of other oral medications, particularly those requiring rapid absorption or those with narrow therapeutic windows. Patients taking levothyroxine, oral contraceptives, or medications for chronic conditions should inform their prescriber during consultation. The 30-minute fasting period after taking oral semaglutide helps minimise most interaction risks, but your clinical team will review your complete medication list to ensure safe prescribing.

Medical Assessment Process at Cured Pharmacy

Our online consultation takes under 3 minutes to complete and covers your medical history, current medications, previous weight loss attempts, and any contraindications to GLP-1 therapy. A UK-registered prescriber reviews every assessment individually—we never use automated approvals. If oral GLP-1 medication is appropriate and safe for you, your prescriber issues a prescription and our pharmacy team dispenses genuine UK-licensed medication. If oral formulations aren't suitable, your prescriber may recommend alternative treatments such as injectable GLP-1 options or other weight management medications available through Cured Pharmacy.

Side Effects and Safety Considerations for Oral GLP-1

Gastrointestinal side effects represent the most common adverse reactions with oral GLP-1 medications. In clinical trials, nausea occurred in approximately 44% of participants taking oral semaglutide compared to 17% with placebo, whilst diarrhoea affected 31% versus 16%, and vomiting occurred in 24% versus 6% [1]. These effects typically emerge during dose escalation and often diminish over time as your body adjusts to the medication. Starting at a lower dose and increasing gradually helps minimise these symptoms.

Most gastrointestinal side effects are mild to moderate in severity and resolve within several weeks. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help manage symptoms. If side effects become severe or persistent, your prescriber may slow the dose escalation schedule or maintain you at a lower dose. Approximately 4-7% of clinical trial participants discontinued oral semaglutide due to gastrointestinal adverse events [1].

Serious adverse effects are rare but require immediate medical attention. These include signs of pancreatitis (severe persistent abdominal pain radiating to the back), gallbladder problems (pain in the upper right abdomen, fever, yellowing of skin or eyes), severe allergic reactions, and symptoms of thyroid tumours (lump in the neck, difficulty swallowing, persistent hoarseness). Hypoglycaemia can occur when oral GLP-1 is used alongside insulin or sulfonylureas, requiring dose adjustments of these medications [2]. Your prescriber at Cured Pharmacy provides comprehensive safety information and monitoring guidance when initiating treatment.

Long-Term Safety and Monitoring

Long-term safety data for oral semaglutide continues to accumulate through ongoing post-marketing surveillance and extension studies. Current evidence shows a safety profile consistent with injectable GLP-1 formulations, with cardiovascular safety established in dedicated outcome trials [3]. Regular monitoring includes assessment of weight loss progress, tolerability, and any emerging health concerns. At Cured Pharmacy, our clinical team provides ongoing support throughout your treatment journey, with follow-up consultations to review progress and adjust therapy as needed. Treatment should be discontinued if you haven't achieved at least 5% weight loss after 3-6 months at the maintenance dose, as per NICE recommendations [4].

Scientific References

1. Knop, F. K., et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10403), 705–719. https://doi.org/10.1016/S0140-6736(23)01185-6
2. Buckley, S. T., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. https://doi.org/10.1126/scitranslmed.aar7047
3. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
4. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to medication, dietary modifications, and lifestyle changes.